Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord.
Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord.
复制标题
在大鼠脊髓中吗啡增加了免疫反应性胆囊收缩素八肽的释放,CCKB 受体拮抗剂 L-365,260 增强了 mu-阿片类镇痛作用。
DOI:
10.1016/0014-2999(93)90948-h
复制
发表时间:
1993
影响因子:
5
通讯作者:
Han,JS
中科院分区:
文献类型:
--
作者:
Zhou,Y;Sun,YH;Zhang,ZW;Han,JS
This is the first report showing, in an in vivo study, that systematic morphine produced a marked (89%, P < 0.01) increase of the cholecystokinin octapeptide (CCK-8) immunoreactivity in the perfusate of the rat spinal cord, an effect completely reversed by naloxone. Since CCK-8 has been shown to possess potent anti-opioid activitit at a spinal level, a blockade of the spinal cholecystokinin effect would be expected to potentiate opiate analgesia. With tail flick latency as a nociceptive index, it was found that intrathecal (i.t.) injection of a novel CCKBantagonist L-365,260 produced a marked potentiation of the analgesic effect induced by the μ-opioid agonists morphine (4 mg/kg s.c.) or ohmefentanyl (32 ng i.t.). Similar effects were obtained with the CCKAantagonist devazepide at a dose 40–50 times higher than that of L-365,260. Both devazepide and L-365,260 showed a bell-shaped dose-response curve. The results confirm the notion that an increased release of CCK-8 may constitute a self-limiting process for opioid effects at the spinal level, and that it is the CCKBreceptor which mediates the anti-opioid effect of CCK-8 in the rat spinal cord.